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Abstract
To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid
profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN). This investigation was
conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN. This randomized, double-blind,
controlled clinical trial was performed among 60 patients with DN. Patients were randomly allocated into two groups to receive
either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (108 CFU/
g) or 25 g/day control honey (n = 30 each group) for 12 weeks. Fasting blood samples were taken at baseline and 12 weeks after
supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress. After 12 weeks
of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin
levels (− 1.2 ± 1.8 vs. − 0.1 ± 1.3μIU/mL,P = 0.004) and homeostasis model of assessment-estimated insulin resistance (− 0.5 ± 0.6
vs. 0.003 ± 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 ± 0.009 vs. − 0.0007 ±
0.005, P = 0.004). Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in
total-/HDL-cholesterol (− 0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04). Probiotic honey intake significantly reduced serum high-sensitivity C-
reactive protein (hs-CRP) (− 1.9 ± 2.4 vs. − 0.2 ± 2.7 mg/L, P = 0.01) and plasmamalondialdehyde (MDA) levels (− 0.1 ± 0.6 vs. +
0.6 ± 1.0 μmol/L, P = 0.002) compared with the control honey. Probiotic honey intake had no significant effects on other metabolic
profiles compared with the control honey. Overall, findings from the current study demonstrated that probiotic honey consumption
for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma
MDA levels, but did not affect other metabolic profiles. http://www.irct.ir: IRCT201705035623N115.
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Introduction
Diabetic kidney disease (DKD) is one of the most complica-
tions of diabetes mellitus and is the main cause of end-stage
kidney disease in the worldwide [1]. Diabetic patients suffered
from classical diabetic nephropathy (DN), which starts with
glomerular hyperfiltration, followed by multiple complications
such as microalbuminuria, macroalbuminuria, and nephrotic-
range proteinuria [2]. DKD is a serious complication that in-
fluences 20% to 40% of all diabetics [3]. Hyperglycemia and
insulin resistance are well-known risk factors for DKD and it
recognized that intensive glycemic control decreases the risk of
DKD [4]. In addition, several studies have reported relations
between systemic markers of inflammation and oxidative
stress and the progress of DN [5, 6].
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It has been documented that the progressive loss of kidney
function significantly contributes to worsen the intestinal
dysbiosis found in patients with DN [7]. Different mecha-
nisms including hypervolemia and intestinal ischemia caused
by aggressive ultrafiltration volumes or intradialytic hypoten-
sion are involved due to derangement of the intestinal barrier
and modifications of microbiota composition [8]. Few studies
have reported the beneficial effects of probiotics on kidney
function and metabolic status in patients with DKD. Bacillus
coagulans is a lactic acid producing bacterial species, which is
catalase positive, spore forming, motile, and a facultative an-
aerobe [9]. Spores of Bacillus coagulans have strong resis-
tance, resurrection, and stability, can be activated in the acidic
environment of the stomach, and begin germinating and pro-
liferating in the gut [10, 11]. Few studies have reported the
beneficial effects of Bacillus coagulans intake on metabolic
profiles and biomarkers of inflammation and oxidative stress
in patients without DN [12, 13]. In addition, in a study by
Abbasi et al. [14], consuming probiotic soy milk for 8 weeks
by patients with DN significantly improved indexes of kidney
function. In addition, we have previously demonstrated that
probiotic supplementation for 12 weeks to diabetic hemodial-
ysis people had beneficial effects on glycemic control, and
some biomarkers of inflammation and oxidative stress, but
did not affect lipid profiles [15]. Moreover, in a meta-
analysis conducted by Yao et al. [16], probiotics supplemen-
tation was correlated with significant improvement in HbA1c,
fasting insulin, and insulin resistance in people with type 2
diabetes mellitus (T2DM), but did not influence fasting glu-
cose and lipid profiles.
These discrepancies may be due to the variation in the
population studied, type, and different dosages of probiotic
used, duration of intervention, underlying levels of metabolic
profiles. Despite these findings, there is still limited evidence
suggesting whether or how Bacillus coagulans could affect
glycemic control, lipid profiles, biomarkers of inflammation,
and oxidative stress in DN patients. The current trial was to
investigate the effects of probiotic honey intake on metabolic
status in DN patients.
Materials and Methods
Participants and Ethics Statements
This randomized, double-blind, controlled clinical trial, in the
Iranian website for registration of clinical trials (no:
IRCT201705035623N115), was conducted among partici-
pants with DN with a proteinuria level > 0.3 g/24 h, aged
45–85 years old referred to Akhavan Clinic in Kashan, Iran
from April 2017 to December 2017. We defined DN as dia-
betic renal disease with proteinuria, with or without elevation
of serum creatinine levels [17]. The exclusion criteria were as
follows: history of active infection within 3 months, the intake
of probiotic and/or synbiotic supplements within 3 months,
and malignancy and/or liver cirrhosis. To determine sample
size, we used the standard formula suggested for parallel clin-
ical trials by considering type 1 error (α) of 0.05 and type 2
error (β) of 0.20 (power = 80%). Based on a previous study
[18], we used 1.86 as SD and 1.50 as the difference in mean
(d) of the homeostasis model of assessment-insulin resistance
(HOMA-IR) as key variable. Based on this, we needed 25
participants in each group. Considering five dropouts in each
group, the final sample size was determined to be 30 partici-
pants per group. This investigation was conducted in accor-
dance with the Declaration of Helsinki. The informed written
consent was taken from all enrolled patients, with ethical
clearance for the study obtained from the ethics committee
of Kashan University of Medical Sciences (KAUMS).
Study Design
Initially, 60 patients with DN were randomly divided into two
groups to receive either 25 g/day probiotic honey containing a
viable and heat-resistant probiotic Bacillus coagulans T4
(IBRC-N10791) (108 CFU/g) or 25 g/day control honey (n =
30 each group) for 12 weeks. Probiotic and control honey were
produced by Gaz Sekkeh Company (Isfahan, Iran). Due to
viability against the high temperature, acidity of the stomach,
bile acids, and growth at physiological conditions as well as
beneficial effects on the intestinal environment, stool frequency,
and characteristics [19], we selected Bacillus coagulans than
other probiotic species. The viability of Bacillus coagulanswas
assessed in the laboratory of Food and Drug Administration in
Tehran, Iran and in the laboratory of Gaz Sekkeh Company
(Isfahan, Iran). Also, the viability of Bacillus coagulans was
re-assessed by the first investigator (NM) in the laboratory of
Food and Drug Administration in Kashan, Iran, at weeks 6 and
12 of the intervention. Randomization was done using a ran-
dom number table by one of the investigators who had no
clinical involvement in the study. Compliance to the intake of
probiotic and control honey was evaluated through receiving
short messages on cell phones by patients. All patients com-
pleted 3-day food records and three physical activity records at
weeks 0, 4, 9, and 12 of the intervention. Macro- and micro-
nutrient intake was analyzed by nutritionist IV software (First
Databank, San Bruno, CA). Anthropometric measurements
were quantified in an overnight fasting status using a digital
scale (Seca, Hamburg, Germany) at baseline and after the 12-
week intervention. Body mass index (BMI) was calculated by
weight and height measurements (weight (kg)/height (m2)).
Outcomes
Primary outcomes were parameters of insulin metabolism in
the current study. Secondary outcome variables were fasting
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plasma glucose (FPG), lipid profiles, biomarkers of inflamma-
tion, and oxidative stress, serum creatinine, blood urea nitro-
gen (BUN) concentrations. Before the onset and after the end
of the intervention, 10-mL fasting blood samples were obtain-
ed from each patient at Kashan reference laboratory. Available
commercial kits were used to determine FPG, lipid profiles,
creatinine, and BUN concentrations (Pars Azmun, Tehran,
Iran) with inter- and intra-assay coefficient variances (CVs)
for FPG, lipid concentrations, creatinine, and BUN that were
less than 5%. Serum insulin levels were assessed using an
ELISA kit (Monobind, California, USA) with the intra- and
inter-assay CVs lower than 6%. To determine the HOMA-IR
and the quantitative insulin sensitivity check index (QUICKI),
we used from suggested formulas [20]. Serum hs-CRP con-
centrations were quantified by an ELISA kit (LDN, Nordhorn,
Germany) with the intra- and inter-assay CVs lower than 7%.
The plasma NO concentrations by the use of Griess method
[21], plasma TAC levels using ferric reducing antioxidant
power (FRAP) developed by Benzie and Strain [22], total
glutathione (GSH) using Beutler et al . [23] and
malondialdehyde (MDA) concentrations by the use of the
thiobarbituric acid reactive substances (TBARs) spectropho-
tometric test [24] were assessed with the intra- and inter-assay
CVs lower than 4%.
Statistical Methods
We applied the Kolmogrov-Smirnov test to evaluate the nor-
mal distribution of variables. The analyses were carried out
based on intention-to-treat (ITT) principle. To detect differ-
ences in anthropometric measures and dietary intakes between
the two groups, we applied independent t test. To determine
the effects of probiotic honey intake on metabolic profiles, we
used one-way repeated measures analysis of variance. P
values < 0.05 were considered statistically significant. All sta-
tistical analyses were done by the use of the Statistical
Package for Social Science version 18 (SPSS Inc., Chicago,
Illinois, USA).
Results
Among patients in the probiotic honey group, two patients
[withdrawn (n = 2)] and in the control honey group, one per-
son [withdrawn (n = 1)] were excluded (Fig. 1). Finally, 57
participants [probiotic honey (n = 28) and control honey
(n = 29)] completed the trial. However, as the analysis was
done based on ITT principle, all 60 participants (30 in each
group) were included in the final analysis.
Mean age, height, baseline weight, and BMI of study par-
ticipants were not statistically different between the two
groups (Table 1).
Based on the 3-day dietary records obtained throughout the
trial, we found no significant change in dietary macro- and
micro-nutrient intakes (data not shown).
After 12 weeks of intervention, patients who received pro-
biotic honey compared with the control honey had significantly
decreased serum insulin levels (− 1.2 ± 1.8 vs. − 0.1 ± 1.3 μIU/
mL, P = 0.004) and HOMA-IR (− 0.5 ± 0.6 vs. 0.003 ± 0.4,
P = 0.002) and significantly improved QUICKI (+ 0.005 ±
0.009 vs. − 0.0007 ± 0.005, P = 0.004) (Table 2). Additionally,
compared with the control honey, probiotic honey intake has
resulted in a significant reduction in total-/HDL-cholesterol (−
0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04). Probiotic honey intake sig-
nificantly reduced serum hs-CRP (− 1.9 ± 2.4 vs. − 0.2 ±
2.7 mg/L, P = 0.01) and plasma MDA levels (− 0.1 ± 0.6 vs.
+ 0.6 ± 1.0 μmol/L, P = 0.002) compared with the control hon-
ey. Probiotic honey intake had no significant effects on other
metabolic profiles compared with the control honey.
Discussion
In the current investigation, we evaluated the effects of probi-
otic honey intake on glucose homeostasis parameters, lipid
profiles, biomarkers of inflammation, and oxidative stress
among patients with DN. We found that probiotic honey con-
sumption for 12 weeks among DN patients had beneficial
effects on insulin metabolism, total-/HDL-cholesterol, serum
hs-CRP, and plasma MDA levels, but did not affect other
metabolic profiles. To the best of our knowledge, this study
is the first indicating the effects of probiotic honey intake on
glycemic control, lipid concentrations, biomarkers of inflam-
mation, and oxidative stress in patients with DN.
Effects of Glycemic Control and Lipid Profiles
DN is correlated with multiple metabolic disturbances, such as
impaired glucose and lipid metabolism, and increased bio-
markers of inflammation and oxidative [25]. The current study
demonstrated that probiotic honey intake for 12 weeks among
patients with DN resulted in a significant reduction in serum
insulin, HOMA-IR and total-/HDL-cholesterol, and a signifi-
cant increase in QUICKI score compared with the control
honey, but did not affect other lipid profiles. Earlier, the ben-
eficial effects of probiotics on glycemic control and lipid pro-
files have reported. In a meta-analysis conducted by Yao et al.
[16], probiotics supplementation resulted in a significant im-
provement in HbA1c and fasting insulin in patients with
T2DM, but did not affect FPG, HOMA-IR, and lipid profiles.
In addition, two previous meta-analyses with smaller numbers
of studies have documented that probiotics significantly im-
proved insulin resistance and significantly decreased glycated
hemoglobin levels [26, 27]. A most recent meta-analysis, with
11 RCTs and 614 patients, also reported similar results [28]. In
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another meta-analysis conducted by He et al. [29], probiotic
supplementation to patients with T2DM significantly de-
creased triglycerides, total- and LDL-cholesterol levels, but
did not influence other lipid profiles. Furthermore, consump-
tion of a synbiotic food containing Bacillus coagulans and
inulin for 9 weeks by pregnant women significantly reduced
insulin and HOMA-IR and significantly increased QUICKI
score [18]. In another study, oral spore-based probiotic sup-
plementation containing Bacillus coagulans, Bacillus
licheniformis, and Bacillus clausii to healthy subjects for
30 days significantly decreased triglycerides and interleukin
12 levels [30]. Administering of a probiotic/prebiotic blend
containing 4.5 billion live cells of Bacillus coagulans and
galactomannans (300 mg) to obese patients for 3 months re-
duced triglycerides and LDL-cholesterol levels [12].
Discrepancies in these findings may be due to differences in
study design, characteristics of study populations, and dosage
of probiotic used, kind of bacteria used, and duration of the
intervention. Insulin resistance and dyslipidemia are two ma-
jor risk factors for T2DM and cardiovascular disease (CVD)
[31]. Accumulating studies demonstrate that restoration of
impaired function of the diabetic macro- and microvasculature
may ameliorate a range of CVD states and diabetes-associated
complications [32]. Therefore, Bacillus coagulans due to their
beneficial effects on markers of insulin metabolism may be
useful to reduce complications related to diabetes. Improved
glycemic control and lipid profiles following the consumption
of probiotics by patients with DNmay be related to decreasing
cytokines and suppressing the nuclear factor-κB pathway
[33], the effect on gene expression related to insulin and lipid
metabolism [34] and gut microbiota-short chain fatty acid
(SCFA)-hormone axis [35].
Randomized (n=60)
Allocated to control (n=30)
Lost to follow-up (n=2)
- Withdrawn (n=2)
Analyzed with ITT (n=30)
Allocated to intervention (n=30)
Lost to follow-up (n=1)
- Withdrawn (n=1)
Analyzed with ITT (n=30)
Assessed for eligibility (n=65)
Excluded (n=5) 
- Not meeting inclusion criteria (n=5) 
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Fig. 1 Summary of patient flow
diagram
Table 1 General characteristics
of study participants Control honey (n = 30) Probiotic honey (n = 30) P
a
Age (year) 60.3 ± 8.5 62.7 ± 9.1 0.29
Height (cm) 159.6 ± 9.5 162.2 ± 8.9 0.14
Weight at study baseline (kg) 78.0 ± 12.5 79.6 ± 15.0 0.64
Weight at end-of-trial (kg) 77.9 ± 12.9 79.3 ± 15.4 0.70
Weight change (kg) − 0.1 ± 1.1 − 0.3 ± 1.4 0.41
BMI at study baseline (kg/m2) 31.1 ± 4.6 30.3 ± 5.6 0.56
BMI at end-of-trial (kg/m2) 31.0 ± 4.8 30.2 ± 5.8 0.53
BMI change (kg/m2) − 0.1 ± 0.4 − 0.1 ± 0.5 0.48
Data are means ± SDs
aObtained from independent t test
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Effects on Biomarkers of Inflammation and Oxidative
Stress
Findings from the present study documented that taking
probiotic honey for 12 weeks by patients with DN was
associated with a significant decrease in serum hs-CRP
and MDA levels compared with the control honey, but
did not influence other biomarkers of inflammation and
oxidative stress. CRP is a key inflammatory marker for
diabetes progression and complications [36]. We have pre-
viously shown that probiotic supplementation for 9 weeks
to pregnant women improved biomarkers of inflammation
and oxidative stress [37]. In addition, probiotic supplemen-
tation for 8 weeks to women with rheumatoid arthritis im-
proved inflammatory cytokines [38]. In an animal study,
supplementing Bacillus coagulans had beneficial effects
on promoting nutrients’ metabolism, maintaining intestinal
integrity, and alleviating oxidative stress [39]. Moreover,
cell walls from the live Bacillus coagulans GBI-30 and
6086 strain have demonstrated immune modulating and
anti-inflammatory effects in vitro [40]. Daily consumption
of Bacillus coagulans BC30 by adults aged 65–80 years
for 28 days could potentially increase production of anti-
inflammatory cytokines [13]. Results from a recent clinical
trial suggested that the consumption of Bacillus coagulans
BC30 in combination with protein by male subjects for
2 weeks tended to reduce indices of muscle oxidative dam-
age [41]. However, a previous meta-analysis presented
non-significant effects of probiotics on CRP concentra-
tions [26]. These results suggest that probiotics may have
an important role in intestinal immunological modulation
[42]. With inflammatory markers and signaling pathways
as key mediators, targeting inflammation may be a useful
approach to new avenue for treating diabetic events [31].
In addition, oxidative stress has been documented to play
important role in the pathogenesis of DN [43]. Probiotic
intake might improve inflammatory markers and oxidative
stress through the increasing production of short chain fat-
ty acids (SCFA) in the gut [44]. SCFA may decrease in-
flammation and oxidative stress through blocking the en-
zymatic synthesis of hepatic CRP [45].
Limitations of our study include the absence of fecal sam-
ple data to demonstrate transit of the specific probiotic through
the gastrointestinal tracts of study subjects in the intervention
group. Moreover, we did not assess gene expression related to
insulin and lipid metabolism. We believe that yeast compared
with bacilli better tolerates in the high sugar content. This
should be considered in the interpretation of our findings.
Table 2 Metabolic profiles, biomarkers of inflammation, and oxidative stress at study baseline and after 3-month intervention in patients with diabetic
nephropathy that received either probiotic or control honey
Control honey (n = 30) Probiotic honey (n = 30) Pa
Wk0 Wk12 Change Wk0 Wk12 Change
FPG (mg/dL) 122.7 ± 35.1 124.3 ± 31.0 1.6 ± 18.2 132.8 ± 37.9 127.1 ± 34.9 − 5.7 ± 20.3 0.14
Insulin (μIU/mL) 16.1 ± 4.5 16.0 ± 4.6 − 0.1 ± 1.3 16.7 ± 5.9 15.5 ± 6.0 − 1.2 ± 1.8 0.004
HOMA-IR 4.9 ± 2.1 4.9 ± 2.2 0.003 ± 0.4 5.5 ± 2.2 5.0 ± 2.2 − 0.5 ± 0.6 0.002
QUICKI 0.30 ± 0.01 0.30 ± 0.01 − 0.0007 ± 0.005 0.30 ± 0.02 0.30 ± 0.02 0.005 ± 0.009 0.004
Triglycerides (mg/dL) 137.8 ± 44.5 138.2 ± 41.5 0.3 ± 27.2 124.4 ± 34.7 122.1 ± 34.7 − 2.3 ± 25.2 0.70
VLDL-cholesterol (mg/dL) 27.6 ± 8.9 27.7 ± 8.3 0.1 ± 5.4 24.9 ± 6.9 24.4 ± 6.9 − 0.5 ± 5.0 0.70
Total cholesterol (mg/dL) 164.7 ± 29.9 167.1 ± 28.8 2.4 ± 18.9 159.7 ± 38.7 154.5 ± 35.9 − 5.2 ± 22.9 0.16
LDL-cholesterol (mg/dL) 92.2 ± 28.8 95.2 ± 27.1 3.0 ± 17.9 90.2 ± 35.3 84.8 ± 33.2 − 5.5 ± 22.9 0.11
HDL-cholesterol (mg/dL) 44.9 ± 7.3 44.3 ± 5.9 − 0.7 ± 3.1 44.6 ± 9.2 45.3 ± 9.3 0.7 ± 2.7 0.07
Total-/HDL-cholesterol ratio 3.7 ± 0.7 3.8 ± 0.6 0.1 ± 0.4 3.6 ± 0.7 3.4 ± 0.6 − 0.2 ± 0.5 0.04
hs-CRP (mg/L) 5.6 ± 3.4 5.4 ± 3.9 − 0.2 ± 2.7 6.9 ± 2.6 5.0 ± 3.5 − 1.9 ± 2.4 0.01
NO (μmol/L) 30.3 ± 4.0 30.6 ± 4.0 0.3 ± 2.3 30.0 ± 1.4 29.8 ± 1.8 − 0.2 ± 1.3 0.25
TAC (mmol/L) 1035.5 ± 151.8 1064.8 ± 162.3 29.3 ± 72.9 989.1 ± 80.9 1065.1 ± 213.3 75.9 ± 214.3 0.26
GSH (μmol/L) 406.7 ± 83.4 417.3 ± 63.8 10.6 ± 55.0 351.6 ± 82.4 391.6 ± 99.2 39.9 ± 106.9 0.18
MDA (μmol/L) 2.5 ± 0.4 3.1 ± 0.8 0.6 ± 1.0 2.7 ± 0.3 2.6 ± 0.5 − 0.1 ± 0.6 0.002
BUN (mg/dL) 19.6 ± 6.2 19.9 ± 7.3 0.3 ± 4.3 19.6 ± 7.1 19.3 ± 6.8 − 0.3 ± 2.1 0.54
Creatinine (mg/dL) 1.3 ± 0.5 1.5 ± 0.8 0.2 ± 0.7 1.6 ± 0.6 1.5 ± 0.5 − 0.1 ± 0.5 0.09
Data are means ± SDs
aObtained from repeated measures ANOVA test
BUN blood urea nitrogen, FPG fasting plasma glucose,GSH total glutathione,HOMA-IR homeostasis model of assessment-estimated insulin resistance,
hs-CRP high-sensitivity C-reactive protein, MDA malondialdehyde, NO nitric oxide, QUICKI quantitative insulin sensitivity check index, TAC total
antioxidant capacity
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Conclusions
Overall, findings from the current study demonstrated that
probiotic honey consumption for 12 weeks among DN pa-
tients had beneficial effects on insulin metabolism, total-/
HDL-cholesterol, serum hs-CRP, and plasma MDA levels,
but did not affect other metabolic profiles.
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